Quick Facts

• Primary Focus: Management of diffuse hair loss.
• Secondary Support: May assist in addressing non-scarred hair growth disorders.
• Hair Structure: May support the structure of thin, stressed, or brittle hair.
• Nail Support: May assist in managing nail growth disorders, such as brittle or splintering nails.

---

Pantogar is a formulation that may be used for the management of diffuse hair loss of unknown origin. Diffuse hair loss occurs when the hair growth cycle is disrupted, leading to increased shedding across the scalp. The ingredients are intended to support the hair root's metabolic processes, which may help to restore the natural growth balance. This may result in a reduction of hair loss over the recommended treatment course.

Additionally, this product may offer support for improving the structure of hair that is considered brittle, fragile, dull-looking, or inelastic. It is also utilized in the supportive treatment of various hair growth disorders that are not hormone-related or scarred. The preparation is also indicated for managing certain nail growth disorders, which can manifest as brittle or splintering nails, by aiming to provide support to the nail structure. Treatment should be supervised by a qualified medical professional, and it is not intended for cases of hormone-related hair loss.

Regulatory References

1. EMA therapeutic overview for nationally authorised medicines

Eligibility Map: Who can and cannot use Pantogar — official regulatory information

Eligibility Scope	Status
Populations for whom use is allowed	Adults (18 years and older); both male and female patients.
Populations for whom use is not recommended	Children under 12 years; Pregnant women; Lactating women.
Populations for whom use is contraindicated	Individuals with known hypersensitivity or allergy to any component of the capsule.

Age and Condition-Specific Eligibility Rules

Specific Restriction	Regulatory Status
Pediatric Use	Use is not recommended in children under 12 years due to a lack of specific tolerability data.
Pregnancy/Lactation Status	Not recommended/Should not be taken due to the lack of sufficient data on safety in these populations.
Significant Renal Impairment	Use is restricted in patients with non-normal serum creatinine levels.
Significant Hepatic Impairment	Use is restricted in patients with elevated liver transaminases (AST/ALT greater than 2.5x the upper limit of normal).

Connection to the Overall Eligibility Profile

Official regulatory documents define eligibility for Pantogar primarily by establishing an absolute exclusion for individuals with hypersensitivity to any component. Further restrictions classify use as not recommended for children under 12 and for women who are pregnant or breastfeeding, citing a lack of specific safety data in these vulnerable populations. Eligibility is also conditionally constrained by organ function integrity, restricting use in patients with significant renal or hepatic impairment based on authoritative clinical standards.

Interactions with other medicines and products

The interaction profile for the Pantogar capsule formulation is defined by its nationally authorized regulatory labeling, which specifies interaction-related constraints and classifications. This section outlines the documented information concerning co-administered medicinal products, focusing exclusively on the official regulatory statements and restrictions.

Interaction Scope

Category	Documented Constraint
Medicinal product categories with documented interactions	Sulfonamide Antibiotics
Mechanistic basis of interactions	Pharmacodynamic Antagonism
Interaction-related restrictions	Co-administration requires medical consultation (precautionary warning).

Interaction Classifications

Classification	Documented Finding
Interaction severity classification	Use-with-caution / Precautionary Warning
Interaction-context constraints	Tied to the Para-aminobenzoic acid (PABA) content in the formulation.

Official Interaction Statements

The official labeling for Pantogar capsules establishes a specific interaction caution involving Sulfonamide Antibiotics.

• The active component Para-aminobenzoic acid (PABA) is the basis for this warning, as it is a known chemical antagonist to the antibacterial action of Sulfonamide Antibiotics.
• The regulatory documentation does not list any formally contraindicated combinations, mandatory administration timing requirements, or population-specific interaction considerations.
• No pharmacokinetic interactions, such as those related to CYP enzymes or drug transporters, are explicitly described in the official interaction profile.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents establish the interaction structure around a single, specific pharmacodynamic precaution. The profile is otherwise characterized by the absence of documented constraints regarding dose timing, exposure-modifying effects, or formal contraindications with other co-administered medicinal products.

Pantogar's mechanism of action involves the targeted delivery of specific micronutrients and amino acids to the hair follicle, the primary site of action being the follicular matrix. The formulation supplies cysteine, a sulfur-containing amino acid, which acts as a foundational precursor for the biosynthesis of alpha-keratin and the formation of disulfide bonds. These bonds contribute to the tensile strength and structural integrity of the hair shaft.

The complex further provides thiamine (Vitamin B1) and calcium pantothenate (Vitamin B5), which serve as essential cofactors in the high metabolic and energy-producing pathways of rapidly dividing keratinocytes. This availability of cofactors modulates the cellular metabolism necessary for DNA synthesis and cellular mitosis within the hair matrix. Collectively, these inputs influence the hair cycle dynamics, specifically by modulating the duration of the anagen phase (growth phase) and the transition rate from the telogen phase (resting/shedding phase), thereby affecting the total proportion of growing hairs and the biophysical anchoring strength of the fiber.

Administration Guidelines

Pantogar is a pharmaceutical preparation delivered as a hard capsule intended for oral ingestion. The use of this medicine is structured around a fixed daily dosage regimen and a defined treatment duration.

---

Dosing and Administration Protocol

The standard protocol for the use of Pantogar in adults involves a specific, divided daily dose. Administration details are tied to meal times and preparation requirements:

Instruction Category	Usage Rule
Standard Adult Dose	1 capsule three times daily (total of 3 capsules per day)
Dosing Frequency	Administered at a frequency of three times daily (TID)
Timing in Relation to Meals	Must be taken with or immediately after a main meal, with doses spread throughout the day.
Preparation	The capsule must be swallowed whole (unchewed) with a small amount of liquid.

---

Procedural and Duration Constraints

The usage period for Pantogar is a fixed, prolonged course, reflecting the slow nature of hair and nail regeneration. The recommended average duration of treatment is 3 to 6 months, and the course may be continued or repeated if necessary.

Special Population Constraint: The medicine is generally not recommended for use in children under 12 years of age due to a lack of sufficient clinical data in this patient group.

Missed Dose Rule: If a dose is forgotten, the user should not take a double dose to compensate, but rather continue the course with the next regularly scheduled dose.

Pantogar: Recent Clinical Evidence

Clinical evidence regarding the efficacy of the multicomponent oral preparation Pantogar primarily focuses on its use in treating diffuse hair loss (telogen effluvium) and addressing structural changes in hair and nail growth. Diffuse hair loss is a condition characterized by increased hair shedding distributed across the entire scalp, often triggered by stress, illness, dietary deficiencies, or hormonal changes.

---

Efficacy in Telogen Effluvium

Recent randomized, double-blind, placebo-controlled studies, which represent the highest standard of evidence, have investigated Pantogar's impact on women diagnosed with telogen effluvium. Key findings from these trials support a beneficial role for the supplement in this condition:

• Anagen Hair Rate: The active compound has been shown to lead to a statistically significant improvement and normalization of the mean anagen hair rate (the percentage of hair follicles in the active growth phase) within a six-month treatment period, compared to the placebo group. This suggests that the supplement may help return a higher proportion of hair to the growth phase, effectively reducing hair shedding.
• Clinical Improvement: Patients receiving the active treatment often report an improvement in the appearance of hair growth, which is also reflected in assessments by independent investigators.

---

Safety and Tolerability

Overall, clinical experience and controlled studies indicate that Pantogar is generally well-tolerated. Reported side effects are typically minor and transient. The most common adverse events, which are rare, have included temporary gastrointestinal disturbances such as stomach discomfort or gas. No serious safety concerns have been widely reported in the medical literature. Treatment is typically recommended for a duration of three to six months to align with the natural hair growth cycle.

---

Summary of Key Findings

Parameter	Observed Effect in Clinical Trials (vs. Placebo)
Anagen Hair Rate	Statistically significant increase and normalization
Hair Shedding	Reduction in hair loss after several months of use
Tolerability	Generally well-tolerated, with rare and minor GI side effects

Common questions about Pantogar (FAQ)

Q: What is Pantogar and what is it used for?

A: Pantogar is an oral treatment indicated for certain types of hair loss (diffuse alopecia) and nail growth disorders. It is classified as a medical food or supplement in some regions and a drug in others.

It is a combination preparation that typically contains a high concentration of B vitamins (like B1 and B5), yeast, L-cysteine, and keratin. It is believed to provide the necessary nutrients to the hair roots and nail matrix to support healthy growth.

Q: How should I take Pantogar?

A: The standard dosage for adults is usually one capsule taken three times a day with a small amount of liquid, and it should be taken with meals. It is important to follow the specific dosing instructions provided by a healthcare professional or listed on the product packaging.

• Consistency is key: Treatment success often depends on taking the capsules regularly over an extended period.
• Duration: Due to the slow growth rate of hair and nails, a treatment course typically lasts 3 to 6 months or longer.

Q: Can Pantogar cause side effects?

A: Pantogar is generally well-tolerated when taken as directed. However, as with any medical product, side effects can occur.

Reported side effects are usually mild and may include:

• Gastrointestinal disturbances, such as stomach discomfort or flatulence.
• Allergic skin reactions, such as hives or itching.

If you experience any concerning side effects, especially signs of a severe allergic reaction (like swelling or difficulty breathing), you should stop taking the product and seek immediate medical attention.

Q: Can pregnant or breastfeeding women take Pantogar?

A: Generally, Pantogar is not recommended for use during the first trimester of pregnancy.

• Use during the later stages of pregnancy or while breastfeeding should only be done under the advice and supervision of a healthcare professional.
• The decision to use the product must balance the potential benefits against any potential risks to the fetus or infant.

Always consult with a doctor before starting any new medication or supplement if you are pregnant, planning to become pregnant, or breastfeeding.

Q: What should I do if I miss a dose?

A: If you miss a dose of Pantogar, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule.

Do not double the dose to make up for a missed one, as this does not increase efficacy and may increase the risk of side effects.

How to Store and Dispose of Pantogar Capsules

Official regulatory guidelines mandate specific storage conditions to ensure the stability of Pantogar capsules, particularly regarding temperature and protection from external factors.

---

Required Storage Conditions

Pantogar must be stored at a temperature not exceeding 25 C. The medicine should be kept in its original packaging to protect the contents from light and ensure a cool, dry environment. Consistent with regulations for all medicinal products, it is mandatory to keep this medicine out of the sight and reach of children.

Disposal Requirements

Unused or expired Pantogar capsules must not be disposed of in wastewater or household waste. The official instruction requires consulting a pharmacist for guidance on the proper disposal of the product, which helps to ensure environmental protection and appropriate pharmaceutical waste handling.